IBDEI2I6 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39966,0)
 ;;=N30.90^^152^2002^20
 ;;^UTILITY(U,$J,358.3,39966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39966,1,3,0)
 ;;=3^Cystitis w/o Hematuria,Unspec
 ;;^UTILITY(U,$J,358.3,39966,1,4,0)
 ;;=4^N30.90
 ;;^UTILITY(U,$J,358.3,39966,2)
 ;;=^5015642
 ;;^UTILITY(U,$J,358.3,39967,0)
 ;;=N41.9^^152^2002^38
 ;;^UTILITY(U,$J,358.3,39967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39967,1,3,0)
 ;;=3^Inflammatory Disease of Prostate,Unspec
 ;;^UTILITY(U,$J,358.3,39967,1,4,0)
 ;;=4^N41.9
 ;;^UTILITY(U,$J,358.3,39967,2)
 ;;=^5015694
 ;;^UTILITY(U,$J,358.3,39968,0)
 ;;=N70.91^^152^2002^75
 ;;^UTILITY(U,$J,358.3,39968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39968,1,3,0)
 ;;=3^Salpingitis,Unspec
 ;;^UTILITY(U,$J,358.3,39968,1,4,0)
 ;;=4^N70.91
 ;;^UTILITY(U,$J,358.3,39968,2)
 ;;=^5015806
 ;;^UTILITY(U,$J,358.3,39969,0)
 ;;=N70.93^^152^2002^74
 ;;^UTILITY(U,$J,358.3,39969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39969,1,3,0)
 ;;=3^Salpingitis & Oophoritis,Unspec
 ;;^UTILITY(U,$J,358.3,39969,1,4,0)
 ;;=4^N70.93
 ;;^UTILITY(U,$J,358.3,39969,2)
 ;;=^5015808
 ;;^UTILITY(U,$J,358.3,39970,0)
 ;;=N70.92^^152^2002^55
 ;;^UTILITY(U,$J,358.3,39970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39970,1,3,0)
 ;;=3^Oophoritis,Unspec
 ;;^UTILITY(U,$J,358.3,39970,1,4,0)
 ;;=4^N70.92
 ;;^UTILITY(U,$J,358.3,39970,2)
 ;;=^5015807
 ;;^UTILITY(U,$J,358.3,39971,0)
 ;;=N73.9^^152^2002^37
 ;;^UTILITY(U,$J,358.3,39971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39971,1,3,0)
 ;;=3^Inflammatory Disease Female Pelvic,Unspec
 ;;^UTILITY(U,$J,358.3,39971,1,4,0)
 ;;=4^N73.9
 ;;^UTILITY(U,$J,358.3,39971,2)
 ;;=^5015820
 ;;^UTILITY(U,$J,358.3,39972,0)
 ;;=A56.11^^152^2002^36
 ;;^UTILITY(U,$J,358.3,39972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39972,1,3,0)
 ;;=3^Inflammatory Disease Chlamydial Female Pelvic
 ;;^UTILITY(U,$J,358.3,39972,1,4,0)
 ;;=4^A56.11
 ;;^UTILITY(U,$J,358.3,39972,2)
 ;;=^5000342
 ;;^UTILITY(U,$J,358.3,39973,0)
 ;;=N73.5^^152^2002^64
 ;;^UTILITY(U,$J,358.3,39973,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39973,1,3,0)
 ;;=3^Peritonitis Female Pelvic,Unspec
 ;;^UTILITY(U,$J,358.3,39973,1,4,0)
 ;;=4^N73.5
 ;;^UTILITY(U,$J,358.3,39973,2)
 ;;=^5015817
 ;;^UTILITY(U,$J,358.3,39974,0)
 ;;=N72.^^152^2002^35
 ;;^UTILITY(U,$J,358.3,39974,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39974,1,3,0)
 ;;=3^Inflammatory Disease Cervix Uteri
 ;;^UTILITY(U,$J,358.3,39974,1,4,0)
 ;;=4^N72.
 ;;^UTILITY(U,$J,358.3,39974,2)
 ;;=^5015812
 ;;^UTILITY(U,$J,358.3,39975,0)
 ;;=N76.3^^152^2002^92
 ;;^UTILITY(U,$J,358.3,39975,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39975,1,3,0)
 ;;=3^Vulvitis,Subacute & Chronic
 ;;^UTILITY(U,$J,358.3,39975,1,4,0)
 ;;=4^N76.3
 ;;^UTILITY(U,$J,358.3,39975,2)
 ;;=^5015829
 ;;^UTILITY(U,$J,358.3,39976,0)
 ;;=N76.1^^152^2002^88
 ;;^UTILITY(U,$J,358.3,39976,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39976,1,3,0)
 ;;=3^Vaginitis,Subacute & Chronic
 ;;^UTILITY(U,$J,358.3,39976,1,4,0)
 ;;=4^N76.1
 ;;^UTILITY(U,$J,358.3,39976,2)
 ;;=^5015827
 ;;^UTILITY(U,$J,358.3,39977,0)
 ;;=N76.2^^152^2002^91
 ;;^UTILITY(U,$J,358.3,39977,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39977,1,3,0)
 ;;=3^Vulvitis,Acute
 ;;^UTILITY(U,$J,358.3,39977,1,4,0)
 ;;=4^N76.2
 ;;^UTILITY(U,$J,358.3,39977,2)
 ;;=^5015828
 ;;^UTILITY(U,$J,358.3,39978,0)
 ;;=N76.0^^152^2002^87
 ;;^UTILITY(U,$J,358.3,39978,1,0)
 ;;=^358.31IA^4^2
